Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH [benign prostatic hyperplasia]: an Open-Labeled Safety and Efficacy Assessment Study.

Trial Profile

Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH [benign prostatic hyperplasia]: an Open-Labeled Safety and Efficacy Assessment Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Registrational
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 17 Aug 2009 Status changed from active, no longer recruiting to completed as reported in an AEterna Zentaris media release.
    • 15 Jun 2009 Data analysis has been brought foward from the scheduled fourth quarter into the third quarter of 2009, according to a AEterna Zentaris media release.
    • 14 May 2008 Status changed from recruiting to in progress, according to AEterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top